Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia



Rating:

Share or cite this content

Citations should be made in the following way:
L. Thong Wan Yin (Co. Cork, Ireland), B. Bowen (Co. Cork, Ireland), M. Henry (Co. Cork, Ireland). Real-life data on the safety and tolerability of Pirfenidone versus Nintedanib in Idiopathic Pulmonary Fibrosis (IPF) patients: A single-centre retrospective study. 463

Member's Comments

No comment yet.

Related content which might interest you: Efficacy and safety of nintedanib in a Greek multicentre idiopathic pulmonary fibrosis registry: a retrospective, observational, cohort study Source: ERJ Open Res, 6 (1) 00172-2019; 10.1183/23120541.00172-2019 Year: 2020 Late Breaking Abstract - Effectiveness and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) from a large Italian practice cohort Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018 Nintedanib in Idiopathic Pulmonary Fibrosis: a single-centre real-life experience Source: International Congress 2017 – IPF: from the bench to the bedside Year: 2017 PROOF: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting in Belgium and Luxembourg: Exposure in the interim report of 175 IPF patients Source: International Congress 2016 – IPF clinical Year: 2016 Comparison of Interferon gamma-1b (IFN-γ)and colcicine in the treatment of Idiopathic pulmonary fibrosis: preliminary results of a prospective, multicenter randomised study Source: Eur Respir J 2002; 20: Suppl. 38, 599s Year: 2002 Prevalence of cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study Source: International Congress 2018 – Consequences of idiopathic interstitial pneumonias Year: 2018 Preliminary results of a prospective, multicentric randomized study comparing Interferon Gamma-1b (IFN-γ) and colchicine in the treatment of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2003 - Interstitial lung diseases Year: 2003 The long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): Interim data from the RECAP extension study Source: Annual Congress 2011 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2011 Pirfenidone post-authorization safety registry (PASSPORT) update Source: International Congress 2015 – Treatment of IPF Year: 2015 Lung cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis Year: 2019 Long-term safety of pirfenidone in RECAP, an open-label extension study in patients with idiopathic pulmonary fibrosis, interim results Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Pirfenidone post-authorization safety registry (PASSPORT) – Interim analysis of IPF treatment Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Recent clinical trials in idiopathic pulmonary fibrosis and the BUILD-1 study Source: Eur Respir Rev 2008; 17: 116-122 Year: 2008 Late Breaking Abstract - Pharmacokinetics (PK) of nintedanib with add-on pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): results from INJOURNEY Source: International Congress 2017 – Lung fibrosis: basic science Year: 2017 Lung cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study in Europe. Source: Virtual Congress 2021 – The future of idiopathic pulmonary fibrosis Year: 2021 Home oxygen saturation monitoring and quality of life in patients with idiopathic pulmonary fibrosis: A prospective multicenter trial Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis of 4 clinical trials Source: International Congress 2016 – IPF treatment I Year: 2016 Inhaled beclomethasone/formoterol in idiopathic pulmonary fibrosis: a randomised controlled exploratory study Source: ERJ Open Res, 3 (4) 00100-2017; 10.1183/23120541.00100-2017 Year: 2017 Clinical profile and early follow-up of patients receiving pirfenidone in the PIONEER observational study Source: International Congress 2014 – ILDs 6 Year: 2014 Post-marketing surveillance of pirfenidone for idiopathic pulmonary fibrosis in Japan: Interim analysis of 973 patients Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012